Advertisement
Canada markets closed

  • S&P/TSX

    22,259.47
    +312.06 (+1.42%)
     

  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     

  • DOW

    38,852.27
    +176.59 (+0.46%)
     

  • CAD/USD

    0.7317
    +0.0009 (+0.12%)
     

  • CRUDE OIL

    78.63
    +0.52 (+0.67%)
     

  • Bitcoin CAD

    86,193.54
    -1,084.98 (-1.24%)
     

  • CMC Crypto 200

    1,359.72
    +47.10 (+3.59%)
     

  • GOLD FUTURES

    2,333.90
    +25.30 (+1.10%)
     

  • RUSSELL 2000

    2,059.25
    +23.52 (+1.16%)
     

  • 10-Yr Bond

    4.4890
    -0.0110 (-0.24%)
     

  • NASDAQ

    16,349.25
    +192.92 (+1.19%)
     

  • VOLATILITY

    13.48
    -0.01 (-0.07%)
     

  • FTSE

    8,213.49
    +41.34 (+0.51%)
     

  • NIKKEI 225

    38,236.07
    -38.03 (-0.10%)
     

  • CAD/EUR

    0.6793
    +0.0006 (+0.09%)
     
MARKETS LIVE BLOG:

STOCKS CLIMB AS RALLY CONTINUES ON FED HOPES

Boeing falls after FAA launches new probe into company's 787 Dreamliner

Integer (ITGR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Equity Research
·2 min read

Integer (ITGR) reported $414.81 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 9.5%. EPS of $1.14 for the same period compares to $0.87 a year ago.

The reported revenue represents a surprise of +0.37% over the Zacks Consensus Estimate of $413.29 million. With the consensus EPS estimate being $1.12, the EPS surprise was +1.79%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

ADVERTISEMENT

Here is how Integer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenue- IMC - Cardio & Vascular: $221.84 million versus $217.54 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +16% change.

  • Revenue- IMC - Cardiac Rhythm Management & Neuromodulation: $156.26 million versus the three-analyst average estimate of $157.63 million. The reported number represents a year-over-year change of +7.7%.

  • Revenue- IMC - Advanced Surgical, Orthopedics & Portable Medical: $29.12 million compared to the $26.96 million average estimate based on three analysts. The reported number represents a change of +4.3% year over year.

  • Revenue- Total Medical Sales: $407.21 million versus $402.15 million estimated by two analysts on average.

  • Revenue- Non-Medical: $7.59 million versus the two-analyst average estimate of $11.79 million. The reported number represents a year-over-year change of -47.7%.

View all Key Company Metrics for Integer here>>>

Shares of Integer have returned +7.1% over the past month versus the Zacks S&P 500 composite's -3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Integer Holdings Corporation (ITGR) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research